762 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
April Retail Sales Down And Stocks Sold Off, I See Opportunities https://seekingalpha.com/article/4694432-april-retail-sales-down-and-stocks-sold-off-i-see-opportunities?source=feed_all_articles May 19, 2024 - CPI data for April came in lower than expected. Read why opportunities for investment and trading can be found in ABNB, UBER, and AFRM despite recent sell-offs.
Nvidia and 2 other portfolio stocks report earnings next week. Here's what we want to see from each https://www.cnbc.com/2024/05/18/nvidia-tjx-palo-alto-networks-report-earnings-next-week.html May 18, 2024 - There will be less economic data in the week ahead, but we will get earnings from three portfolio names, including one of our two "own, don't trade" stocks.
Wall Street Analysts See Modine (MOD) as a Buy: Should You Invest? https://www.zacks.com/stock/news/2275326/wall-street-analysts-see-modine-mod-as-a-buy-should-you-invest?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2275326 May 17, 2024 - Based on the average brokerage recommendation (ABR), Modine (MOD) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
AZUL Posts Wider-Than-Expected Q1 Loss, Sees Y/Y Revenue Rise https://www.zacks.com/stock/news/2275076/azul-posts-wider-than-expected-q1-loss-sees-y-y-revenue-rise?cid=CS-ZC-FT-analyst_blog|earnings_article-2275076 May 16, 2024 - Azul's first-quarter 2024 revenues benefit from buoyant travel demand.
U.S. Stocks Seeing Modest Strength, Dow Climbs Above 40,000 For First Time https://www.rttnews.com/story.aspx?Id=3448471 May 16, 2024 - Stocks are seeing modest strength during trading on Thursday, extending the rally seen in the previous session. The major averages have reached new record highs, with the Dow climbing above 40,000 for the first time. The major averages have pulled back off their highs in recent trading but currently remain in positive territory.
Wall Street Analysts See Teekay Tankers (TNK) as a Buy: Should You Invest? https://www.zacks.com/stock/news/2274685/wall-street-analysts-see-teekay-tankers-tnk-as-a-buy-should-you-invest?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2274685 May 16, 2024 - According to the average brokerage recommendation (ABR), one should invest in Teekay Tankers (TNK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Wall Street Analysts See Nextracker (NXT) as a Buy: Should You Invest? https://www.zacks.com/stock/news/2274687/wall-street-analysts-see-nextracker-nxt-as-a-buy-should-you-invest?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2274687 May 16, 2024 - The average brokerage recommendation (ABR) for Nextracker (NXT) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Wall Street Analysts See a 36.02% Upside in Geopark (GPRK): Can the Stock Really Move This High? https://www.zacks.com/stock/news/2274180/wall-street-analysts-see-a-36-02-upside-in-geopark-gprk-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2274180 May 15, 2024 - The average of price targets set by Wall Street analysts indicates a potential upside of 36% in Geopark (GPRK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts See a 69.15% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High? https://www.zacks.com/stock/news/2274184/wall-street-analysts-see-a-69-15-upside-in-fulcrum-therapeutics-fulc-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2274184 May 15, 2024 - The consensus price target hints at a 69.2% upside potential for Fulcrum Therapeutics (FULC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
SCHE: I See More Downside Than Upside For Emerging Markets (Rating Downgrade) https://seekingalpha.com/article/4693417-sche-i-see-more-downside-than-upside-for-emerging-markets-rating-downgrade?source=feed_tag_etf_portfolio_strategy May 15, 2024 - China's dominance in the EM indices is a key reason for Schwab Emerging Markets Equity ETF's underperformance. See why I downgrade SCHE from buy to hold.

Pages: 1...3839404142434445464748...77

<<<Page 43>